Do BI-RADS 4 or 5 Require Biopsy With Fibrocystic Breasts?
At a Glance
Fibrocystic breast changes can cause familiar lumps, but they do not rule out cancer when imaging is suspicious. A BI-RADS 4 or 5 finding generally needs an image-guided biopsy, and the tissue result is compared with the images.
If diagnostic imaging assigns a finding BI-RADS 4 or BI-RADS 5, a biopsy is strongly recommended, even if you have a history of fibrocystic breast changes and the lump feels exactly like a familiar cyst [1][2]. It can be incredibly frustrating to hear that a familiar-feeling lump needs further testing, but a biopsy is the standard next step to determine exactly what the tissue is [3].
Why Imaging Outweighs How a Lump Feels
When you have fibrocystic breast changes, your breasts may naturally feel lumpy. Because of this, it can be confusing when a doctor recommends a biopsy for something that feels normal to you. However, medical studies show that a physical examination—simply feeling the lump—is not enough to safely eliminate the possibility of breast cancer [4]. Some cancerous lesions (areas of abnormal tissue) can mimic the smooth or firm feel of a cyst.
Imaging technologies like mammograms or ultrasounds look deeper. If the radiologist sees signs such as irregular shapes, spiculated margins (irregular, spike-like edges), or certain calcifications (tiny calcium deposits), these features may prompt a suspicious assessment [5][6]. A genuinely simple cyst is usually considered benign on ultrasound, but if it has a thick wall or solid components (making it a complex cyst), it may be flagged.
Understanding BI-RADS 4 and 5
BI-RADS (Breast Imaging Reporting and Data System) is a standardized reporting and assessment system used widely for breast imaging. A score of 4 or 5 is an assessment of the likelihood of malignancy (cancer) based on visual features [7], not a definitive diagnosis.
- BI-RADS 4 (Suspicious Abnormality): This means the finding is suspicious enough that a biopsy is generally recommended [1]. Because this category is broad, it is broken down into population-level likelihood ranges:
- BI-RADS 5 (Highly Suggestive of Malignancy): This means the area has classic imaging features of breast cancer, with an intended probability of 95% or higher [8].
Because actual rates vary based on age and the specific imaging methods used [9][10], tissue testing is strongly recommended to confirm a diagnosis before deciding on any next steps. Do not wait to see if the lump changes; it is best to contact your care team promptly to arrange the recommended follow-up.
What to Expect From a Biopsy
To find out exactly what the lump is, your doctor will likely recommend a biopsy to sample the tissue [11]. While an image-guided core needle biopsy (using a hollow needle guided by ultrasound or mammogram) is very common [3], other methods include vacuum-assisted or MRI-guided biopsies, or sometimes a surgical excision (removing the area with surgery) depending on the lesion.
Usually, a core needle biopsy is an outpatient procedure done with local anesthetic (numbing medicine). You may experience some bruising or soreness afterward. The doctor may also leave a tiny metal marker clip in the breast so the exact spot can be found on future scans. Results typically take a few days to a week.
The Role of Pathology and “Concordance”
A pathologist will examine the sampled tissue under a microscope to identify benign conditions (like fibrocystic changes), atypical cells (abnormal cells that aren’t cancer but may increase risk), or cancer [12][13].
Once the pathology report returns, your doctor and radiologist will check for radiology-pathology concordance [14]. They will ask: Does this biopsy result make sense given how suspicious the imaging looked?
- Concordant: If the imaging looked somewhat like a complicated cyst and the biopsy confirms it is a fibrocystic change, the results are “concordant” (they match). Your doctor will then recommend a specific follow-up plan, which may be routine screening or short-term monitoring.
- Discordant: If the imaging looked highly suspicious (like a BI-RADS 5) but the biopsy only shows normal tissue, the results are “discordant.” The doctor may suspect sampling error (the needle missed the target) and may recommend a repeat biopsy or surgical excision to be absolutely certain [15][16].
Common questions in this guide
Can fibrocystic breasts explain a BI-RADS 4 or 5 result without a biopsy?
What is the difference between BI-RADS 4 and BI-RADS 5?
What biopsy is usually done for a suspicious breast finding?
What happens if the biopsy is benign after a BI-RADS 4 or 5 result?
Should I wait to see whether a BI-RADS 4 or 5 lump changes?
Related questions
Show more
Get notified when new evidence is published on breast fibrocystic disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (16)
- 1
MRI in the Assessment of BI-RADS® 4 lesions.
Leithner D, Wengert G, Helbich T, et al.
Topics in magnetic resonance imaging : TMRI 2017; (26(5)):191-199 doi:10.1097/RMR.0000000000000138.
PMID: 28961568 - 2
Clinical practice guidelines from the French College of Gynecologists and Obstetricians (CNGOF): benign breast tumors - short text.
Lavoué V, Fritel X, Antoine M, et al.
European journal of obstetrics, gynecology, and reproductive biology 2016; (200()):16-23.
PMID: 26967341 - 3
Sonographic Characteristics and Pathology Correlation of Breast Imaging Reporting and Data System (BI-RADS) Category 4 Lesions.
Khan P, Masroor I, Alam MS, et al.
Cureus 2023; (15(12)):e51410 doi:10.7759/cureus.51410.
PMID: 38292968 - 4
[Exploring a non-inflammatory clinical breast mass: Clinical practice guidelines].
Legendre G, Guilhen N, Nadeau C, et al.
Journal de gynecologie, obstetrique et biologie de la reproduction 2015; (44(10)):904-12.
PMID: 26541562 - 5
Nonpalpable BI-RADS 4 breast lesions: sonographic findings and pathology correlation.
Elverici E, Barça AN, Aktaş H, et al.
Diagnostic and interventional radiology (Ankara, Turkey) 2015; (21(3)):189-94 doi:10.5152/dir.2014.14103.
PMID: 25835079 - 6
Diagnostic accuracy of digital breast tomosynthesis in combination with 2D mammography for the characterisation of mammographic abnormalities.
Sanmugasiva VV, Ramli Hamid MT, Fadzli F, et al.
Scientific reports 2020; (10(1)):20628 doi:10.1038/s41598-020-77456-6.
PMID: 33244075 - 7
Value of breast MRI omics features and clinical characteristics in Breast Imaging Reporting and Data System (BI-RADS) category 4 breast lesions: an analysis of radiomics-based diagnosis.
Cui Q, Sun L, Zhang Y, et al.
Annals of translational medicine 2021; (9(22)):1677 doi:10.21037/atm-21-5441.
PMID: 34988186 - 8
BI-RADS Category 5 Assessments at Diagnostic Breast Imaging:Outcomes Analysis Based on Lesion Descriptors.
Yao MM, Joe BN, Sickles EA, Lee CS
Academic radiology 2019; (26(8)):1048-1052 doi:10.1016/j.acra.2018.07.018.
PMID: 30195413 - 9
The Utility of the Fifth Edition of the BI-RADS Ultrasound Lexicon in Category 4 Breast Lesions: A Prospective Multicenter Study in China.
Gu Y, Tian JW, Ran HT, et al.
Academic radiology 2022; (29 Suppl 1()):S26-S34 doi:10.1016/j.acra.2020.06.027.
PMID: 32768352 - 10
Does patient age affect the PPV3 of ACR BI-RADS Ultrasound categories 4 and 5 in the diagnostic setting?
Hu Y, Yang Y, Gu R, et al.
European radiology 2018; (28(6)):2492-2498 doi:10.1007/s00330-017-5203-3.
PMID: 29302783 - 11
Histopathological Correlation of Breast Carcinoma with Breast Imaging-Reporting and Data System.
Aziz S, Mohamad MA, Md Zin RR
The Malaysian journal of medical sciences : MJMS 2022; (29(4)):65-74 doi:10.21315/mjms2022.29.4.7.
PMID: 36101539 - 12
Diagnostic value of breast ultrasound in mammography BI-RADS 0 and clinically indeterminate or suspicious of malignancy breast lesions.
Dobrosavljević A, Rakić S, Nikoli B, et al.
Vojnosanitetski pregled 2016; (73(3)):239-45 doi:10.2298/vsp140508001d.
PMID: 27295907 - 13
The Evolving Role of Vacuum Assisted Biopsy of the Breast: A Progression from Fine-Needle Aspiration Biopsy.
Bennett IC, Saboo A
World journal of surgery 2019; (43(4)):1054-1061 doi:10.1007/s00268-018-04892-x.
PMID: 30617562 - 14
Pathologic High-risk Lesions, Diagnosis and Management.
Murray M
Clinical obstetrics and gynecology 2016; (59(4)):727-732 doi:10.1097/GRF.0000000000000234.
PMID: 27681693 - 15
Idiopathic Granulomatous Mastitis in a Postmenopausal Woman Mimicking Breast Carcinoma: A Diagnostic Challenge.
Xanthopoulou G, Solakis E, Barkolias C, et al.
Cureus 2026; (18(3)):e106027 doi:10.7759/cureus.106027.
PMID: 42051828 - 16
Correlations Between Core Needle Biopsy and Excisional Biopsy Findings in Suspected Breast Lesions: A Single Center Study.
Davidson T, Ravid MM, Nissan E, et al.
The Israel Medical Association journal : IMAJ 2018; (20(7)):401-404.
PMID: 30109786
This page is for informational purposes only and does not constitute medical advice. It explains why BI-RADS 4 or 5 findings are usually evaluated with biopsy despite fibrocystic breast changes; your radiologist or breast care team should interpret your results and timing.